Indivior PLC (NASDAQ:INDV - Get Free Report)'s share price traded down 4.7% during mid-day trading on Wednesday . The stock traded as low as $10.92 and last traded at $10.86. 350,553 shares were traded during mid-day trading, a decline of 68% from the average session volume of 1,104,098 shares. The stock had previously closed at $11.40.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the company. Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target for the company. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Finally, RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a report on Tuesday, January 28th.
Check Out Our Latest Analysis on Indivior
Indivior Stock Down 10.0 %
The company has a market cap of $1.32 billion, a P/E ratio of -239.44 and a beta of 0.73. The business's 50 day moving average is $11.77 and its 200 day moving average is $11.05.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in Indivior during the 4th quarter worth approximately $56,000. Stifel Financial Corp purchased a new position in shares of Indivior during the third quarter worth $100,000. Melqart Asset Management UK Ltd purchased a new stake in Indivior in the third quarter valued at $132,000. Jane Street Group LLC purchased a new position in shares of Indivior during the 3rd quarter valued at about $180,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Indivior in the 3rd quarter valued at about $294,000. Hedge funds and other institutional investors own 60.33% of the company's stock.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Recommended Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
